Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children

References

• Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510–17. doi:10.1097/INF.0b013e3182184ae7.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, Groome MJ, Cohen C, Moyes J, Thorburn K, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5(10):e984–e991. doi:10.1016/S2214-109X(17)30344-3.
   PubMed Web of Science ®Google Scholar
• Byington CL, Wilkes J, Korgenski K, Sheng X. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics. 2015;135(1):e24–31. doi:10.1542/peds.2014-2151.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, et al.Respiratory Syncytial Virus Network (ReSVINET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–e311. doi:10.1016/S1473-3099(18)30292-5.
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Symons JA, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Res. 2018;155:76‐88. doi:10.1016/j.antiviral.2018.05.005.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, et al. Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015 Nov;3(11):888–900. doi:10.1016/S2213-2600(15)00255-6.
   PubMed Web of Science ®Google Scholar
• Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2018 Dec 18:pii: S1526-0542(18)30139–8. doi:10.1016/j.prrv.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138–49. doi:10.1080/21645515.2017.1337614.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531–37. doi:10.1542/peds.102.3.531.
   Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meer HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–40. doi:10.1067/s0022-3476(03)00454-2.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–20. doi:10.1542/peds.2014-1666.
   PubMedGoogle Scholar
• Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr (Barc). 2015;82(3):199.e1-2. doi:10.1016/j.anpedi.2014.10.004.
   Google Scholar
• Sánchez Luna M, Pérez Muñuzuri A, Leante Castellanos JL, Ruiz Campillo CW, Sanz López E, Benavente Fernández I, Sánchez Redondo MD, Rite Gracia S. en representación de la Comisión de Estándares de la Sociedad Española de Neonatología. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high-risk infants]. An Pediatr (Barc). 2019;91(5):348–50. doi:10.1016/j.anpedi.2019.08.003.
   PubMedGoogle Scholar
• Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738–49. doi:10.1128/JCM.01816-15.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017;30(1):277–319. doi:10.1128/CMR.00010-16.
   PubMed Web of Science ®Google Scholar
• Mansournia MA, Higgins JP, Sterne JA, Hernán MA. Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology. 2017;28(1):54–59. doi:10.1097/EDE.0000000000000564.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704. doi:10.1097/INF.0000000000001533.
   PubMed Web of Science ®Google Scholar
• Viguria N, Martínez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS One. 2018;13(11):e0206474. doi:10.1371/journal.pone.0206474.
   PubMed Web of Science ®Google Scholar
• Haerskjold A, Kristensen K, Kamper-Jørgensen M, Nybo Andersen AM, Ravn H, Graff Stensballe L. Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children. Pediatr Infect Dis J. 2016;35(1):61–65. doi:10.1097/INF.0000000000000924.
   PubMed Web of Science ®Google Scholar
• Lim A, Butt ML, Dix J, Elliott L, Paes B. Respiratory syncytial virus (RSV) infection in children with medical complexity. Eur J Clin Microbiol Infect Dis. 2019;38(1):171–76. doi:10.1007/s10096-018-3409-1.
   PubMed Web of Science ®Google Scholar
• Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol. 2008;42(1):52–57. doi:10.1016/j.jcv.2007.11.012.
   PubMed Web of Science ®Google Scholar
• Gimferrer L, Campins M, Codina MG, Martín MDC, Fuentes F, Esperalba J, Bruguera A, Vilca LM, Armadans L, Pumarola T, et al. Molecular epidemiology and molecular characterization of respiratory syncytial viruses at a tertiary care university hospital in Catalonia (Spain) during the 2013-2014 season. J Clin Virol. 2015;66:27–32. doi:10.1016/j.jcv.2015.02.01.
   PubMed Web of Science ®Google Scholar
• Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, Szilagyi PG, Edwards KM, Staat MA, Hall CB, et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab prophylactic immunization. J Clin Virol. 2015;65:26–31. doi:10.1016/j.jcv.2015.01.016.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927–36. doi:10.1128/AAC.06446-11.
   PubMed Web of Science ®Google Scholar
• Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114(5):e554–e556. doi:10.1542/peds.2004-0226.
   PubMed Web of Science ®Google Scholar
• Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012;21(1):53–60. doi:10.1002/pds.2246.
   PubMed Web of Science ®Google Scholar
• De Serres G, Skowronski DM, Wu XW, Ambrose C. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill. 2013;18:37. doi:10.1371/journal.pone.0163586.
   Google Scholar
• Rodriguez-Fernandez R, Tapia LI, Yang CF, Torres JP, Chavez-Bueno S, Garcia C, Jaramillo LM, Moore-Clingenpeel M, Jafri HS, Peeples ME, et al. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. J Infect Dis. 2017;217(1):24–34. doi:10.1093/infdis/jix543.
   PubMed Web of Science ®Google Scholar
• Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16(1):46–58. doi:10.18553/jmcp.2010.16.1.46.
   PubMed Web of Science ®Google Scholar
• Stewart DL, Ryan KJ, Seare JG, Pinsky B, Becker L, Frogel M. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infect Dis. 2013;13:334. doi:10.1186/1471-2334-13-334.
   PubMed Web of Science ®Google Scholar
• Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus prophylactic immunization in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J. 2008;27(2):175–76. doi:10.1097/INF.0b013e318159832b.
   PubMed Web of Science ®Google Scholar
• Wong SK, Li A, Lanctôt KL, Paes B. Adherence and outcomes: a systematic review of palivizumab utilization. Expert Rev Respir Med. 2018;12(1):27–42. doi:10.1080/17476348.2018.1401926.
   PubMed Web of Science ®Google Scholar
• Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V. Optimisation de la prévention de la bronchiolite à VRS chez les nouveaux-nés à risque et les prématurés: mesure de l’impact d’une intervention éducative ciblée [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants]. Arch Pediatr. 2015;22(2):146–53. doi:10.1016/j.arcped.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, et al.; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25. doi:10.1056/NEJMoa1913556.
   PubMed Web of Science ®Google Scholar
• Bond HS, Sullivan SG, Cowling BJ. Regression approaches in the test-negative study design for assessment of influenza vaccine effectiveness. Epidemiol Infect. 2016;144(8):1601–11. doi:10.1017/S095026881500309X.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. Geneva; 2017. [accesed 2020 Sept 29]. https://apps.who.int/iris/bitstream/handle/10665/255203/9789241512121-eng.pdf;jsessionid=BF8E8B943503324D3B7CF47325EABD46?sequence=1
   Google Scholar